Pages that link to "Q33360943"
Jump to navigation
Jump to search
The following pages link to Phase II trial of 4'-0-tetrahydropyranyladriamycin (pirarubicin) in head and neck carcinoma (Q33360943):
Displaying 10 items.
- Pirarubicin inhibits multidrug-resistant osteosarcoma cell proliferation through induction of G2/M phase cell cycle arrest (Q33567522) (← links)
- Pirarubicin-based chemotherapy displayed better clinical outcomes and lower toxicity than did doxorubicin-based chemotherapy in the treatment of non-metastatic extremity osteosarcoma (Q34991299) (← links)
- Targeting the MIR34C-5p-ATG4B-autophagy axis enhances the sensitivity of cervical cancer cells to pirarubicin (Q37189149) (← links)
- Recent advances in the discovery and development of topoisomerase inhibitors as antitumor agents (Q41521938) (← links)
- Pharmacokinetics of 4'-O-tetrahydropyranyladriamycin given on a weekly schedule in patients with advanced breast cancer (Q41659189) (← links)
- Therapeutic effect of pirarubicin-based chemotherapy for osteosarcoma patients with lung metastasis (Q43077121) (← links)
- Pirarubicin-based versus doxorubicin-based osteosarcoma chemotherapy (Q44001919) (← links)
- Concurrent chemoradiotherapy with pirarubicin and 5-fluorouracil for resectable oral and maxillary carcinoma (Q45129609) (← links)
- Evaluation of pirarubicin-cisplatin chemotherapy in the treatment for refractory and recurrent high-grade osteosarcoma: experience of a single institute (Q51021522) (← links)
- Adjuvant Therapy of Breast Cancer with Pirarubicin Versus Epirubicin in Combination with Cyclophosphamide and 5-fluorouracil (Q84967048) (← links)